Glycosaminoglycans and mucopolysaccharidosis type III
- PMID: 27100513
- DOI: 10.2741/4463
Glycosaminoglycans and mucopolysaccharidosis type III
Abstract
Mucopolysaccharidosis type III (MPS III), or Sanfilippo syndrome, is a lysosomal storage disease in which heparan sulfate is accumulated in lysosomes, as well as outside of cells, as the primary storage material. This disease is a complex of four conditions caused by dysfunctions of one of genes coding for lysosomal enzymes involved in degradation of heparan sulfate: SGSH (coding for heparan N-sulfatase) - causing MPS IIIA, NAGLU (coding for alpha-N-acetylglucosaminidase) - causing MPS IIIB, HGSNAT (coding for acetyl CoA alpha-glucosaminide acetyltransferase) - causing MPS IIIC), and GNS (coding for N-acetylglucosamine-6-sulfatase) - causing MPS IIID. The primary storage is responsible for some disease symptoms, but other arise as a result of secondary storage, including glycosphingolipids, and subsequent processes, like oxidative stress and neuroinflammation. Central nervous system is predominantly affected in all subtypes of MPS III. Heparan sulfate and its derivatives are the most commonly used biomarkers for diagnosis and prediction procedures. Currently, there is no therapy for Sanfilippo syndrome, however, clinical trials are ongoing for enzyme replacement therapy, gene therapy and substrate reduction therapy (particularly gene expression-targeted isoflavone therapy).
Similar articles
-
Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-N-Acetylglucosamine-6-Sulfatase in Neonatal Mice.Mol Pharm. 2021 Jan 4;18(1):214-227. doi: 10.1021/acs.molpharmaceut.0c00831. Epub 2020 Dec 15. Mol Pharm. 2021. PMID: 33320673 Free PMC article.
-
[Postnatal and prenatal diagnosis of mucopolysaccharidosis type III (Sanfilippo syndrome)].Zhonghua Er Ke Za Zhi. 2008 Jun;46(6):407-10. Zhonghua Er Ke Za Zhi. 2008. PMID: 19099774 Chinese.
-
Lysosomal storage of heparan sulfate causes mitochondrial defects, altered autophagy, and neuronal death in the mouse model of mucopolysaccharidosis III type C.Autophagy. 2016 Jun 2;12(6):1059-60. doi: 10.1080/15548627.2015.1046671. Epub 2015 May 22. Autophagy. 2016. PMID: 25998837 Free PMC article.
-
How close are we to therapies for Sanfilippo disease?Metab Brain Dis. 2018 Feb;33(1):1-10. doi: 10.1007/s11011-017-0111-4. Epub 2017 Sep 18. Metab Brain Dis. 2018. PMID: 28921412 Free PMC article. Review.
-
Mucopolysaccharidosis III (Sanfilippo Syndrome)- disease presentation and experimental therapies.Pediatr Endocrinol Rev. 2014 Sep;12 Suppl 1:133-40. Pediatr Endocrinol Rev. 2014. PMID: 25345095 Review.
Cited by
-
An immune deficient mouse model for mucopolysaccharidosis IIIA (Sanfilippo syndrome).Sci Rep. 2023 Oct 27;13(1):18439. doi: 10.1038/s41598-023-45178-0. Sci Rep. 2023. PMID: 37891179 Free PMC article.
-
Effects of Heparan sulfate acetyl-CoA: Alpha-glucosaminide N-acetyltransferase (HGSNAT) inactivation on the structure and function of epithelial and immune cells of the testis and epididymis and sperm parameters in adult mice.PLoS One. 2023 Sep 27;18(9):e0292157. doi: 10.1371/journal.pone.0292157. eCollection 2023. PLoS One. 2023. PMID: 37756356 Free PMC article.
-
Neurological, neurobehavioral, and radiological alterations in patients with mucopolysaccharidosis III (Sanfilippo's syndrome) in Brazil.Front Neurol. 2022 Nov 17;13:968297. doi: 10.3389/fneur.2022.968297. eCollection 2022. Front Neurol. 2022. PMID: 36468061 Free PMC article.
-
Sanfilippo Syndrome: Optimizing Care with a Multidisciplinary Approach.J Multidiscip Healthc. 2022 Sep 19;15:2097-2110. doi: 10.2147/JMDH.S362994. eCollection 2022. J Multidiscip Healthc. 2022. PMID: 36158637 Free PMC article. Review.
-
Sleep-related hypermotor epilepsy in a patient with mucopolysaccharidosis type III.Sleep Sci. 2021 Jan-Mar;14(Spec 1):97-100. doi: 10.5935/1984-0063.20200113. Sleep Sci. 2021. PMID: 34917281 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources